MaxCyte, Inc. announced that the Biomedical Division of PHC Corporation (PHCbi) has signed an exclusive agreement to distribute the MaxCyte ExPERT platform in Japan. This partnership aims to expand the commercial reach of MaxCyte's cell engineering technology in a key Asian market.
Concurrently, SciMed (Asia) Pte Ltd, a subsidiary of PHC Holdings Corporation, entered into a separate exclusive distribution agreement for the MaxCyte ExPERT platform in Singapore. These agreements leverage established distribution channels to increase market penetration.
These exclusive distribution partnerships are expected to drive the adoption of MaxCyte's Flow Electroporation technology in research, development, and commercialization of cell-based therapeutics within these regions. The agreements are designed to enhance MaxCyte's global footprint and support its growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.